查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
藥物動力學服務市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按藥物類型、服務類型、治療應用、最終用戶和地理位置
市場調查報告書
商品編碼
1498540

藥物動力學服務市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按藥物類型、服務類型、治療應用、最終用戶和地理位置

Pharmacokinetics Services Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Type, Service Type, Therapeutic Application, and End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 174 Pages | 訂單完成後即時交付

價格

藥物動力學服務市場規模預計將從 2023 年的 8.7496 億美元增至 2031 年的 15.7987 億美元。

藥物動力學服務市場的市場促進因素

慢性病和傳染病的盛行率上升

糖尿病、癌症和自體免疫疾病等慢性病的日益普及一直是全世界藥物開發工作的主要動力。根據世界衛生組織（WHO）2024年的資料，全球約有4.22億人患有糖尿病，這些病例大多發生在中低收入國家，每年導致約150萬人死亡。製藥公司處於開發治療各種疾病藥物的前沿。藥物動力學研究對於透過分析人體內吸收、分佈、代謝和消除 (ADME) 的過程來了解這些藥物在患者體內的行為至關重要。藥物吸收到體循環中影響藥物到達作用部位（例如血漿）的速度和濃度。藥物在全身的分佈模式會根據其生化特性和身體生理而改變。代謝涉及身體將藥物加工成後續化合物。此步驟有助於將藥物轉化為水溶性物質，使其適合腎臟清除。代謝對於將可待因等前藥轉化為活性代謝物也很重要。體內藥物的排泄主要受腎臟支配；然而，在某些情況下，藥物可能會經由肺部、皮膚或胃腸道排泄。 ADME 動力學定義了藥物在體內的生物利用度，藥物的維持劑量是根據其清除時間（所需血漿濃度除以生物利用度）計算的。了解清除率可以幫助從業人員計算適當的劑量率。

藥物動力學研究的重點是最佳化研究對象的藥物劑量方案，以了解藥物的功效和安全性。這些研究對於確保長期治療藥物的安全性至關重要，有助於評估藥物配方在慢性病管理中的適用性和穩定性。因此，慢性病和傳染病負擔的增加凸顯了藥物動力學研究對於開發安全有效的個人化治療的重要性。

藥物動力學服務市場的機會

收集和處理藥物製造過程中產生的大量藥物動力學資料是一項昂貴、繁瑣且耗時的任務。這些任務的勞動力和成本密集性質凸顯了對用於預測藥物動力學參數的藥物動力學模擬模型和體外-體內藥物動力學相關模型（IVIVC）等模型的需求。藥物動力學模擬模型是利用計算和數學模型解釋特定條件下生活環境中藥物動力學的工具。此外，IVIVC 模型是藥物發現過程的基本組成部分。在藥物開發的早期階段分析 PK/PD 預測對於先導最佳化策略和進一步降低損耗率是必要的。在開發新的體外和體內策略以改善和表徵藥物動力學特性方面取得了重大進展。 IVIVC 模型被提議作為一種經濟高效的替代方案，用於評估生物製藥特性，分析藥物的生物利用度及其應用。因此，預計此類體內和體外模型將在不久的將來為藥物動力學服務市場提供利潤豐厚的機會。

藥物動力學服務市場：細分概述

依藥物類型分類，市場分為小分子、大分子和疫苗。 2023 年，小分子細分市場佔據最大的市場佔有率。

藥物動力學服務市場依治療應用分為腫瘤學、傳染病、神經系統疾病、自體免疫疾病、婦科疾病、心血管疾病、呼吸系統疾病等。 2023 年，腫瘤學領域佔據最大的市場佔有率。

藥物動力學服務市場：地理概述

北美佔據最大的市場佔有率。根據加拿大政府的報告，加拿大衛生部收到了數百份新的臨床試驗申請，以測試新藥（包括疫苗）或引入已批准藥物的新用途。該國的兒科患者（兒童和青少年）在父母許可的情況下參加臨床試驗。加拿大衛生部保護參與臨床試驗的個人，包括兒童和青少年。根據加拿大臨床試驗資產圖 (CCTAM) 報告，2022 年加拿大註冊了約 3,500 項臨床試驗，其中癌症治療是一個重要的重點領域，2021 年有 1,300 項癌症臨床試驗。創新藥物局的報告，加拿大的臨床研究投入了12 億美元。此外，截至 2021 年，加拿大臨床試驗網路 (CCTN) 保存了超過 600 萬筆病患記錄。因此，臨床試驗和研究數量的增加以及傳染病和慢性疾病盛行率的增加是推動加拿大藥物動力學服務市場成長的因素。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：藥物動力學服務市場格局

  • PEST分析

第 5 章：藥物動力學服務市場 - 主要市場動態

  • 藥物動力學服務市場 - 主要市場動態
  • 市場促進因素
    • 慢性病和傳染病的盛行率上升
    • 擴大藥物動力學研究的應用範圍
    • 將藥物動力學服務外包給 CRO
  • 市場限制
    • 新興國家藥物動力學服務提供者的覆蓋範圍有限
  • 市場機會
    • 擴大採用體內和體外模型來了解藥物動力學的變異性
  • 未來趨勢
    • 藥物動力學服務中越來越多採用巨量資料分析
  • 促進因素和限制的影響：

第 6 章：藥物動力學服務市場 - 全球市場分析

  • 藥物動力學服務市場收入，2023-2031

第 7 章：藥物動力學服務市場分析 - 按藥物類型

  • 概述
  • 小分子
  • 大分子
  • 疫苗

第 8 章：藥物動力學服務市場分析 - 按服務類型

  • 臨床前 ADME 和人體研究
  • PK/PD 分析和報告
  • 劑量模擬
  • 風險分析
  • 其他

第 9 章：藥物動力學服務市場分析 - 按治療應用

  • 腫瘤學
  • 傳染性疾病
  • 神經系統疾病
  • 自體免疫疾病
  • 婦科疾病
  • 心血管疾病
  • 呼吸系統疾病
  • 其他

第 10 章：藥物動力學服務市場分析 - 按最終用戶

  • 製藥和生物技術公司
  • 合約研究組織
  • 其他

第 11 章：藥物動力學服務市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國

到 2031 年，傳染病領域的市場預計價值 1,924 萬美元，預計 2023-2031 年複合年成長率為 10.8%。

      • 英國：藥物動力學服務市場 - 收入和 2031 年預測
      • 義大利：藥物動力學服務市場 - 收入和 2031 年預測
      • 西班牙：藥物動力學服務市場 - 收入和 2031 年預測
      • 歐洲其他地區：藥物動力學服務市場 - 收入和 2031 年預測
  • 亞太地區
    • 亞太地區藥物動力學服務市場概況
    • 亞太地區：藥物動力學服務市場
    • 亞太地區：藥物動力學服務市場 - 收入和預測分析 - 按國家/地區
      • 中國：藥物動力學服務市場 - 收入及 2031 年預測
      • 日本：藥物動力學服務市場 - 收入和 2031 年預測
      • 印度：藥物動力學服務市場 - 收入和 2031 年預測
      • 澳洲：藥物動力學服務市場 - 收入和 2031 年預測
      • 韓國：藥物動力學服務市場 - 收入和 2031 年預測
      • 亞太地區其他地區：藥物動力學服務市場 - 收入和 2031 年預測
  • 中東和非洲
    • 中東和非洲藥物動力學服務市場概況
    • 中東和非洲：藥物動力學服務市場 - 收入和 2031 年預測
    • 按國家/地區分類的藥物動力學服務市場細分
    • 藥物動力學服務市場收入、預測與分析 - 按國家/地區
    • 中東和非洲：藥物動力學服務市場 - 收入和預測分析 - 按國家/地區
      • 沙烏地阿拉伯：藥物動力學服務市場 - 收入和 2031 年預測
      • 南非：藥物動力學服務市場 - 收入和 2031 年預測
      • 阿拉伯聯合大公國：藥物動力學服務市場 - 收入和 2031 年預測
      • 中東和非洲其他地區：藥物動力學服務市場 - 收入和 2031 年預測
  • 南美洲和中美洲
    • 南美洲和中美洲藥物動力學服務市場概述
    • 南美洲和中美洲：藥物動力學服務市場 - 收入和 2031 年預測
    • 按國家/地區分類的藥物動力學服務市場細分
    • 藥物動力學服務市場收入、預測與分析 - 按國家/地區
      • 巴西：藥物動力學服務市場 - 收入和 2031 年預測
      • 阿根廷：藥物動力學服務市場 - 收入和 2031 年預測
      • 南美洲和中美洲其他地區：藥物動力學服務市場 - 收入和 2031 年預測

第 12 章：公司簡介

  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • Evotec SE
  • Certara Inc.
  • Parexel International Corp
  • Thermo Fisher Scientific Inc.
  • Allucent
  • PACIFIC BIOLABS
  • SGS SA
  • Shanghai Medicilon Inc.

第 13 章：附錄

Product Code: TIPRE00007438

The pharmacokinetics services market size is projected to reach US$ 1,579.87 million by 2031 from US$ 874.96 million in 2023. The market is expected to register a CAGR of 7.6% during 2023-2031.

Market Drivers of the Pharmacokinetics Services Market

Rising Prevalence of Chronic and Infectious Diseases

The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune diseases has been a prime enabler of drug development efforts across the world. According to the World Health Organization's (WHO) 2024 data, ~422 million in the world suffer from diabetes, and these cases are mostly found in middle and low-income countries, causing approximately 1.5 million deaths every year. Pharmaceutical companies are at the forefront of developing drugs to treat various diseases. Pharmacokinetic studies are essential for understanding how these drugs behave in a patient's body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body. The absorption of a drug into systemic circulation affects the speed and concentration at which a drug may reach the site of action, e.g., plasma. Drug distribution pattern throughout the body varies based on its biochemical properties and body physiology. Metabolism involves the processing of the drug by the body into subsequent compounds. This step is instrumental in converting the drug into water-soluble substances to render them suitable for renal clearance. Metabolism is also important for the conversion of prodrugs, such as codeine, into active metabolites. Excretion of drugs from the body is mainly governed by kidneys; however, in several cases, drugs may be excreted via the lungs, skin, or gastrointestinal tract. ADME dynamics define the bioavailability of drugs in the body, and the maintenance doses of drugs are calculated based on their clearance times (desired plasma concentration divided by bioavailability). Understanding of clearance allows practitioners to calculate appropriate dosing rates.

Pharmacokinetic studies focus on optimizing drug dose regimens in study subjects to understand the efficacy and safety of a drug. These studies are essential for ensuring the safety of drugs that are developed for long-term treatments, which helps evaluate the suitability and stability of drug formulations in chronic disease management. Hence, the rising burden of chronic and infectious diseases underlines the importance of pharmacokinetic studies to develop safe and effective personalized treatments.

Opportunities in the Pharmacokinetics Services Market

The collection and handling of huge pharmacokinetic data generated during drug manufacturing are expensive, tedious, and time-consuming tasks. The labor- and cost-intensive nature of these tasks highlights the need for models such as pharmacokinetic simulation models and in vitro-in vivo pharmacokinetic correlation models (IVIVC) for the prediction of pharmacokinetic parameters. The pharmacokinetic simulation model is a tool that interprets drug kinetics in the living environment under specific conditions using computational and mathematical models. In addition, the IVIVC model are a fundamental part of the drug discovery process. Analyzing PK/PD predictions at the early stages of drug development is necessary for lead optimization strategies and also to further reduce attrition rates. There have been significant advancements in the development of new in-vitro and in-vivo strategies to improve and characterize pharmacokinetic properties. IVIVC models are being proposed as a cost-effective alternative to assess the biopharmaceutical properties that analyze the bioavailability of drugs and their application. Hence, such in-vivo and in-vitro models are anticipated to provide lucrative opportunities for the pharmacokinetics services market in the near future.

Pharmacokinetics Services Market: Segmental Overview

By drug type, the market is segmented into small molecules, large molecules, and vaccines. The small molecule segment held the largest market share in 2023.

The pharmacokinetics services market, by therapeutic application, is categorized into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

Pharmacokinetics Services Market: Geographical Overview

North America held the largest share of the market. According to a report by the Government of Canada, Health Canada receives hundreds of new clinical trial applications to test new drugs (including vaccines) or to introduce new uses of approved medicines. Pediatric patients (children and youth) in the country participate in clinical trials with their parents' permission. Health Canada protects individuals participating in clinical trials, including children and youth. According to the Canadian Clinical Trials Asset Map (CCTAM) report, ~3,500 clinical trials were registered in Canada in 2022, with cancer therapeutics being a significant area of focus, accounting for 1,300 cancer clinical trials in 2021. The pharmaceutical industry invested ~US$ 1.2 billion in clinical research in Canada, per the Innovative Medicines Canada report. Further, the Canadian Clinical Trials Network (CCTN) had over 6 million patient records maintained as of 2021. Thus, the demand for pharmacokinetic services increases with the surge in drug development and discovery projects in Canada. Thus, the rising number of clinical trials and research studies, and the increasing prevalence of infectious diseases and chronic disorders are among the factors propelling the pharmacokinetics services market growth in Canada.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Pharmacokinetics Services Market Landscape

  • 4.1 PEST Analysis

5. Pharmacokinetics Services Market - Key Market Dynamics

  • 5.1 Pharmacokinetics Services Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic and Infectious Diseases
    • 5.2.2 Expanding Range of Application of Pharmacokinetic Studies
    • 5.2.3 Outsourcing of Pharmacokinetics Services to CROs
  • 5.3 Market Restraints
    • 5.3.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
  • 5.4 Market Opportunities
    • 5.4.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
  • 5.5 Future Trend
    • 5.5.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
  • 5.6 Impact of Drivers and Restraints:

6. Pharmacokinetics Services Market - Global Market Analysis

  • 6.1 Pharmacokinetics Services Market Revenue (US$ Million), 2023-2031

7. Pharmacokinetics Services Market Analysis - by Drug Type

  • 7.1 Overview
  • 7.2 Small Molecule
    • 7.2.1 Overview
    • 7.2.2 Small Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Large Molecule
    • 7.3.1 Overview
    • 7.3.2 Large Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Vaccines
    • 7.4.1 Overview
    • 7.4.2 Vaccines: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Pharmacokinetics Services Market Analysis - by Service Type

  • 8.1 Pre-Clinical ADME and Human Studies
    • 8.1.1 Overview
    • 8.1.2 Pre-Clinical ADME and Human Studies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 PK/PD Analysis and Reporting
    • 8.2.1 Overview
    • 8.2.2 PK/PD Analysis and Reporting: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Dosing Simulations
    • 8.3.1 Overview
    • 8.3.2 Dosing Simulations: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Risk Analysis
    • 8.4.1 Overview
    • 8.4.2 Risk Analysis: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Pharmacokinetics Services Market Analysis - by Therapeutic Application

  • 9.1 Oncology
    • 9.1.1 Overview
    • 9.1.2 Oncology: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Infectious Diseases
    • 9.2.1 Overview
    • 9.2.2 Infectious Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Neurological Disorders
    • 9.3.1 Overview
    • 9.3.2 Neurological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Autoimmune Diseases
    • 9.4.1 Overview
    • 9.4.2 Autoimmune Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Gynecological Disorders
    • 9.5.1 Overview
    • 9.5.2 Gynecological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.6 Cardiovascular Diseases
    • 9.6.1 Overview
    • 9.6.2 Cardiovascular Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.7 Respiratory Disorders
    • 9.7.1 Overview
    • 9.7.2 Respiratory Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.8 Others
    • 9.8.1 Overview
    • 9.8.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Pharmacokinetics Services Market Analysis - by End User

  • 10.1 Pharmaceutical and Biotechnology Companies
    • 10.1.1 Overview
    • 10.1.2 Pharmaceutical and Biotechnology Companies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Contract Research Organization
    • 10.2.1 Overview
    • 10.2.2 Contract Research Organization: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Others
    • 10.3.1 Overview
    • 10.3.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11. Pharmacokinetics Services Market - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Pharmacokinetics Services Market Overview
    • 11.1.2 North America: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
      • 11.1.2.1 United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.1.1 Overview
        • 11.1.2.1.2 United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.1.3 United States: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.2.1.4 United States: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.2.1.5 United States: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.2.1.6 United States: Pharmacokinetics Services Market Breakdown, by End User
      • 11.1.2.2 Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.2.1 Overview
        • 11.1.2.2.2 Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.2.3 Canada: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.2.2.4 Canada: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.2.2.5 Canada: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.2.2.6 Canada: Pharmacokinetics Services Market Breakdown, by End User
      • 11.1.2.3 Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.3.1 Overview
        • 11.1.2.3.2 Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.3.3 Mexico: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.2.3.4 Mexico: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.2.3.5 Mexico: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.2.3.6 Mexico: Pharmacokinetics Services Market Breakdown, by End User
  • 11.2 Europe
    • 11.2.1 Europe Pharmacokinetics Services Market Overview
    • 11.2.2 Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.2.3 Pharmacokinetics Services Market Breakdown by Countries
    • 11.2.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
      • 11.2.4.1 Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.1.1 Overview
        • 11.2.4.1.2 Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.1.3 Germany: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.1.4 Germany: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.1.5 Germany: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.2.4.1.6 Germany: Pharmacokinetics Services Market Breakdown, by End User
      • 11.2.4.2 France: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.2.1 Overview
        • 11.2.4.2.2 France: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.2.3 France: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.2.4 France: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.2.5 France: Pharmacokinetics Services Market Breakdown, by Therapeutic Application

The market for infectious diseases segment is estimated to be worth US$ 19.24 million by 2031 and is expected to register a CAGR of 10.8% during the 2023-2031.

        • 11.2.4.2.6 France: Pharmacokinetics Services Market Breakdown, by End User
      • 11.2.4.3 United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.3.1 Overview
        • 11.2.4.3.2 United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.3.3 United Kingdom: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.3.4 United Kingdom: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.3.5 United Kingdom: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.2.4.3.6 United Kingdom: Pharmacokinetics Services Market Breakdown, by End User
      • 11.2.4.4 Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.4.1 Overview
        • 11.2.4.4.2 Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.4.3 Italy: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.4.4 Italy: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.4.5 Italy: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.2.4.4.6 Italy: Pharmacokinetics Services Market Breakdown, by End User
      • 11.2.4.5 Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.5.1 Overview
        • 11.2.4.5.2 Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.5.3 Spain: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.5.4 Spain: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.5.5 Spain: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.2.4.5.6 Spain: Pharmacokinetics Services Market Breakdown, by End User
      • 11.2.4.6 Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.6.1 Overview
        • 11.2.4.6.2 Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.6.3 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.6.4 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.6.5 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.2.4.6.6 Rest of Europe: Pharmacokinetics Services Market Breakdown, by End User
  • 11.3 Asia Pacific
    • 11.3.1 Asia Pacific Pharmacokinetics Services Market Overview
    • 11.3.2 Asia Pacific: Pharmacokinetics Services Market
    • 11.3.3 Asia Pacific: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
      • 11.3.3.1 China: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.1.1 Overview
        • 11.3.3.1.2 China: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.1.3 China: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.1.4 China: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.1.5 China: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.1.6 China: Pharmacokinetics Services Market Breakdown, by End User
      • 11.3.3.2 Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.2.1 Overview
        • 11.3.3.2.2 Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.2.3 Japan: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.2.4 Japan: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.2.5 Japan: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.2.6 Japan: Pharmacokinetics Services Market Breakdown, by End User
      • 11.3.3.3 India: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.3.1 Overview
        • 11.3.3.3.2 India: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.3.3 India: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.3.4 India: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.3.5 India: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.3.6 India: Pharmacokinetics Services Market Breakdown, by End User
      • 11.3.3.4 Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.4.1 Overview
        • 11.3.3.4.2 Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.4.3 Australia: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.4.4 Australia: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.4.5 Australia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.4.6 Australia: Pharmacokinetics Services Market Breakdown, by End User
      • 11.3.3.5 South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.5.1 Overview
        • 11.3.3.5.2 South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.5.3 South Korea: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.5.4 South Korea: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.5.5 South Korea: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.5.6 South Korea: Pharmacokinetics Services Market Breakdown, by End User
      • 11.3.3.6 Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.6.1 Overview
        • 11.3.3.6.2 Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.6.3 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.6.4 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.6.5 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.6.6 Rest of APAC: Pharmacokinetics Services Market Breakdown, by End User
  • 11.4 Middle East and Africa
    • 11.4.1 Middle East and Africa Pharmacokinetics Services Market Overview
    • 11.4.2 Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.4.3 Pharmacokinetics Services Market Breakdown by Countries
    • 11.4.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
    • 11.4.5 Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
      • 11.4.5.1 Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.1.1 Overview
        • 11.4.5.1.2 Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.1.3 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.4.5.1.4 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.4.5.1.5 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.4.5.1.6 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by End User
      • 11.4.5.2 South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.2.1 Overview
        • 11.4.5.2.2 South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.2.3 South Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.4.5.2.4 South Africa: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.4.5.2.5 South Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.4.5.2.6 South Africa: Pharmacokinetics Services Market Breakdown, by End User
      • 11.4.5.3 United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.3.1 Overview
        • 11.4.5.3.2 United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.3.3 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.4.5.3.4 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.4.5.3.5 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.4.5.3.6 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by End User
      • 11.4.5.4 Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.4.1 Overview
        • 11.4.5.4.2 Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.4.3 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.4.5.4.4 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.4.5.4.5 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.4.5.4.6 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by End User
  • 11.5 South and Central America
    • 11.5.1 South and Central America Pharmacokinetics Services Market Overview
    • 11.5.2 South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.5.3 Pharmacokinetics Services Market Breakdown by Countries
    • 11.5.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
      • 11.5.4.1 Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.1.1 Overview
        • 11.5.4.1.2 Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.1.3 Brazil: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.5.4.1.4 Brazil: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.5.4.1.5 Brazil: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.5.4.1.6 Brazil: Pharmacokinetics Services Market Breakdown, by End User
      • 11.5.4.2 Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.2.1 Overview
        • 11.5.4.2.2 Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.2.3 Argentina: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.5.4.2.4 Argentina: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.5.4.2.5 Argentina: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.5.4.2.6 Argentina: Pharmacokinetics Services Market Breakdown, by End User
      • 11.5.4.3 Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.3.1 Overview
        • 11.5.4.3.2 Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.3.3 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.5.4.3.4 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.5.4.3.5 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.5.4.3.6 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by End User

12. Company Profile

  • 12.1 Charles River Laboratories International Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Eurofins Scientific SE
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Evotec SE
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Certara Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
  • 12.5 Parexel International Corp
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Thermo Fisher Scientific Inc.
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Allucent
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 PACIFIC BIOLABS
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 SGS SA
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Shanghai Medicilon Inc.
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners

List Of Tables

  • Table 1. Pharmacokinetics Services Market Segmentation
  • Table 2. United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 3. United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 4. United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 5. United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 6. Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 7. Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 8. Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 9. Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 10. Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 11. Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 12. Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 13. Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 14. Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 15. Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 16. Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 17. Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 18. France: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 19. France: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 20. France: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 21. France: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 22. United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 23. United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 24. United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 25. United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 26. Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 27. Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 28. Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 29. Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 30. Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 31. Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 32. Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 33. Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 34. Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 35. Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 36. Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 37. Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 38. China: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 39. China: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 40. China: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 41. China: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 42. Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 43. Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 44. Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 45. Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 46. R&D Expenditure of Indian Companies, 2018-2020 (US$ Million)
  • Table 47. Company
  • Table 48. India: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 49. India: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 50. India: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 51. India: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 52. Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 53. Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 54. Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 55. Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 56. South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 57. South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 58. South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 59. South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 60. Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 61. Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 62. Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 63. Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 64. Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 65. Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 66. Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 67. Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 68. South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 69. South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 70. South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 71. South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 72. United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 73. United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 74. United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 75. United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 76. Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 77. Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 78. Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 79. Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 80. Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 81. Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 82. Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 83. Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 84. Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 85. Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 86. Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 87. Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 88. Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 89. Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 90. Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 91. Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User

List Of Figures

  • Figure 1. Pharmacokinetics Services Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Pharmacokinetics Services Market Revenue (US$ Million), 2023-2031
  • Figure 5. Pharmacokinetics Services Market, By Geography Forecast Analysis, 2023 & 2031
  • Figure 6. Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
  • Figure 7. Small Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Large Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Vaccines: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
  • Figure 11. Pre-Clinical ADME and Human Studies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. PK/PD Analysis and Reporting: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Dosing Simulations: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Risk Analysis: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
  • Figure 17. Oncology: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Infectious Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Neurological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Autoimmune Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Gynecological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Cardiovascular Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Respiratory Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
  • Figure 26. Pharmaceutical and Biotechnology Companies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Contract Research Organization: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. North America: Pharmacokinetics Services Market by Key Countries - Revenue (2023) US$ Million
  • Figure 30. North America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. North America: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 32. United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. Europe: Pharmacokinetics Services Market - Revenue by Key Countries Revenue 2023 (US$ Million)
  • Figure 36. Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 37. Europe: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 38. Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. France: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. Asia Pacific: Pharmacokinetics Services Market - Revenue by Key Countries 2023 (US$ Million)
  • Figure 45. Asia Pacific: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Asia Pacific: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 47. China: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 48. Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. India: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 50. Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Middle East and Africa: Pharmacokinetics Services Market by Key Countries - Revenue 2023 (US$ Million)
  • Figure 54. Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Pharmacokinetics Services Market Breakdown by Key Countries, 2023 and 2031 (%)
  • Figure 56. Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 57. Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 60. Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 61. South and Central America: Pharmacokinetics Services Market by Key Countries - Revenue 2023 (US$ Million)
  • Figure 62. South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 63. Pharmacokinetics Services Market Breakdown by Key Countries, 2023 and 2031 (%)
  • Figure 64. Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 65. Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 66. Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)